Compare Panorama Sentrawisata Tbk. (PANR) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Panorama Sentrawisata Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Panorama Sentrawisata Tbk. trades at Rp424 (market cap 588.3B, 111.8K 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Panorama Sentrawisata Tbk. is far larger — about 5.6× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| PANR | SCPI | |
|---|---|---|
Market Cap | 588.3B | 104.4B |
Volume | 111.8K | — |
Lot | 1.12K | — |
Turnover | 46.5M | — |
Average Price | 415.92 | — |
Value | 46.5M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Panorama Sentrawisata Tbk.
PT. Panorama Sentrawisata Tbk (the Company) was established based on Notarial Deed No.71 dated July 22, 1995 and October 1995, of Sugiri Kadarisman, S.H., a public notary in Jakarta. The company has 4 divisions : 1. Inbound tours 2. Outbound Tours and Travel 3. Transportation tours 4. MICE (Meeting, Incentive, Conferences & Exhibition Organizer)
Read more on PANR →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
